Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

ClinicalTrials.gov ID: NCT02659293

Public ClinicalTrials.gov record NCT02659293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 9, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Study identification

NCT ID
NCT02659293
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of Chicago
Other
Enrollment
180 participants

Conditions and interventions

Interventions

  • Carfilzomib Drug
  • Dexamethasone Drug
  • Lenalidomide Drug
  • Lenalidomide (Control) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 25, 2016
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027
Last update posted
Mar 3, 2026

2016 – 2027

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
University of Chicago Chicago Illinois 60637 —
Wayne State University - Karmanos Cacner Institute Detroit Michigan 48201 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02659293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 3, 2026 · Synced May 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02659293 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →